Thyrocare's Docon Sells 9.9% Stake for Rs 986 Crore in Major Deal
Docon Technologies divests 9.9% of its stake in Thyrocare Technologies for Rs 986 crore, reducing its ownership to 51.02%.
In a significant transaction, Docon Technologies, a key promoter of Thyrocare Technologies Ltd, has offloaded a 9.9% stake in the diagnostics firm for Rs 986 crore. This strategic sale was executed through a series of bulk and block deals on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) on Thursday.
Transaction Details and Market Impact
Docon sold 1,57,69,696 equity shares, with more than 1.31 crore shares transacted via block deals. An additional 10 lakh shares were traded through bulk deals on the NSE, while another 16.01 lakh shares were sold through a bulk deal on the BSE. The share prices ranged between Rs 624 and Rs 631.71, culminating in a total transaction value of Rs 985.86 crore.
Following this transaction, Docon's stake in Thyrocare Technologies decreased from 60.92% to 51.02%. The move sparked interest from a diverse group of investors, including institutional investors, insurance companies, and global investment firms.
Investors and Market Response
The stake sale attracted substantial participation from leading mutual funds such as HSBC MF, DSP MF, ICICI Prudential MF, Aditya Birla Sun Life MF, WhiteOak Capital MF, and ITI MF. Additionally, Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance joined the fray, along with Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority, which engaged in block deals on the NSE.
In response to the sale, Thyrocare Technologies' shares saw an uptick, rising nearly 3% to Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE by Friday. The market's positive reception highlights the confidence investors have in the company's future prospects despite the reduction in promoter holding.
Historical Context and Future Implications
This latest divestment follows Docon's previous sale of a 10% stake in Thyrocare for Rs 667 crore in October of the preceding year. The continuous reduction in Docon's stake raises questions about the strategic direction and future ownership structure of the diagnostics giant.
While the specific buyers in the bulk deals remain undisclosed, the involvement of prominent investment entities suggests a robust demand for Thyrocare's shares. The ongoing interest from institutional investors may signal confidence in the company's performance and growth potential in the diagnostics sector.